


## A New Tool to Monitor Breast Cancer Survivors

- ClearID™ is an innovative blood test that sequences the tumor and looks for cancer associated mutations
- Genetic alterations that are found in the blood are matched to current therapeutic options as well as ongoing clinical trials
- Unlike radiographic tools that look for physical changes in the tumor, ClearID looks for the genomic alterations associated with disease
- A simple blood draw, compared to risky and invasive tissue biopsy



### ClearID: The Solution

Clear ID detects genetic alterations in cancer cells and monitors the level of these alterations to help guide treatment decisions in four specific applications:


- Monitoring metastatic breast cancer disease
- Solution when there is a lack of tissue to biopsy or QNS (quantity not sufficient)
- Longitudinal monitoring to assess clinical response to therapy or identifying changes/emergence of new genomic alterations
- Recurrence monitoring for high risk breast cancer survivors

*ClearID complements the Standard of Care (NCCN Guidelines), to alert physicians when aggressive surveillance is required.*

### The Results

ClearID results are summarized in a **patient-specific genomic report** that includes leading-edge, clinically relevant knowledge on current and experimental treatments and diagnostics.

Summary test reports are available within 3-10 days of sample processing.



### ORDERING INFORMATION

For more information and to find out how to order ClearID, give us a call or send us an email.

**Call:** (888) 885-1172  
(805) 855-2050

**Email:** [clientservices@cynvenio.com](mailto:clientservices@cynvenio.com)

